Market News How it works Learn FAQ
| RCT 0.0923 21.29% | NU 12.5021 -17.53% | EWZ 34.02 -20.12% | BBD 2.877 -29.31% | TGL 0.2429 9.66% | AZTR 2.05 186.71% | ITUB 7.68 -20.58% | SRTM 0.2775 -35.51% | NVD 3.995 -4.65% | XP 15.4801 -49.10% | WFF 0.089 11.25% | SHFS 0.091 -31.27% | SPCX 149.37 1.27% | SOXL 92.37 10.54% | PBR 22.715 -13.17% | VALE 11.99 -3.31% | CLRO 4.84 48.92% | INTC 91.75 5.51% | GCDT 0.1443 -18.06% | TSLL 10.885 11.53% | NWGL 0.0872 6.34% | NOK 8.715 7.06% | NVDA 216.1126 2.44% | SOXS 46.95 -10.50% | CRWV 56.22 3.66% | BITO 10.695 -1.25% | RWM 14.475 -0.52% | GPUS 0.1858 10.01% | SGRY 23.185 47.21% | TSLG 5.445 11.81% | ABEV 2.805 -15.00% | JBLU 2.285 -12.95% | IREN 26.025 4.50% | INTR 4.595 -36.09% | RBNE 0.1682 -11.47% | QID 14.1701 -2.61% | AAL 12.1792 0.57% | TQQQ 68.8286 3.83% | SBS 4.6303 -27.65% | SPDN 8.485 -0.64% | TSLA 393.84 5.81% | T 20.6998 -1.10% | LUCD 0.538 30.90% | SID 0.9075 -23.09% | WULF 12.3201 8.83% | XTND 2.2899 29.37% | NFLX 63.005 -4.32% | CIFR 7.885 -0.69% | SQQQ 38.17 -3.81% | RIG 6.555 2.26%
PLPolaryx Therapeutics, Inc. logo

Polaryx Therapeutics, Inc. (PLYX)

NASDAQ Global Market · Currency in USD
$1.81 ▼ -0.05 (-2.43%)
As of Oct 26, 3:02 PM ET. Market open.

Summary

Previous Close
$1.85
Open
$1.92
Day's Range
$1.76 – $1.92
52 Week Range
$1.76 – $48.91
Volume
25,794
Avg. Volume
75,364
Market Cap
$89.97M
Beta (5Y Monthly)
-8.91
PE Ratio (TTM)
--
EPS (TTM)
-$0.14
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$6.50

Profile: Polaryx Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
11
CEO
Alex Yang

Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.06
DateEst.Actual
Aug 13, 2026-$0.04-$0.03Beat
May 15, 2026-$0.02-$0.05Miss
Mar 24, 2026-$0.02-$0.13Miss
Jan 27, 2026–-$0.03

Analyst view

Consensus price target
$6.50 ▲ +260.1%
Range $6.00 – $7.00

Get free alerts on PLYX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.